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Androgen receptor (AR) activation is the primary driving factor in prostate cancerwhich is initially responsive to castration but then
becomes resistant (castration-resistant prostate cancer (CRPC)). CRPC cells still retain the functioning AR which can be targeted
by other therapies. A recent promising development is the use of inhibitors (Epi-1) of protein-protein interaction to inhibit AR-
activated signalling. Translating novel therapies into the clinic requires sensitive early response indicators. Here potential response
markers are explored. Growth inhibition of prostate cancer cells with flutamide, paclitaxel, and Epi-1 was measured using the
MTT assay. To simulate choline-PET scans, pulse-chase experiments were carried out with [3H-methyl]choline and proportion
of phosphorylated activity was determined after treatment with growth inhibitory concentrations of each drug. Extracts from
treated cells were also subject to 31P-NMR spectroscopy. Cells treated with flutamide demonstrated decreased [3H-methyl]choline
phosphorylation, whilst the proportion of phosphorylated [3H-methyl]choline that was present in the lipid fraction was increased
in Epi-1-treated cells. Phospholipid breakdown products, glycerophosphorylcholine and glycerophosphoethanolamine levels, were
shown by 31P-NMR spectroscopy to be decreased to undetectable levels in cells treated with Epi-1. LNCaP cells responding to
treatment with novel protein-protein interaction inhibitors suggest that 31P-NMR spectroscopymay be useful in detecting response
to this promising therapy.
1. Introduction
Prostate cancer is the secondmost commonly diagnosed can-
cer and the 6th leading cause of death in men worldwide [1].
Most prostate cancers are initially sensitive to antiandrogen
treatment and advanced stage cases of prostate cancer are
treated by antiandrogen therapy, for example, by castration,
but such cancers later develop resistance (castrate-resistant
prostate cancer (CRPC)) although they are still dependent on
the AR (androgen receptor) for growth.The taxane docetaxel
has demonstrated some improvement in survival of patients
with CRPC and is recommended for patients with CRPC [2].
The development of AR-targeting compounds that can
inhibit the growth of CRPC cells is a major step forward
in the treatment of this disease. Protein-protein interaction
inhibitors are a rapidly emerging class of drugs in anticancer
drug development which demonstrate effective therapeutic
efficacy towards tumours refractory to other treatments.
Work has demonstrated that targeting the androgen receptor
with the protein-protein inhibitor molecule family 3-(4-{2-
[4-(3-chloro-2-hydroxypropoxy)phenyl]-2-propanyl}phe-
noxy)-1,2-propanediol (Epi-1) can halt the growth of CRPC
cells by inhibiting androgen receptor mediated intracellular
signalling [3].
Anticancer treatments are often associated with detri-
mental side-effects [4, 5]. Early detection of response status
can be used to tailor a patient’s treatment facilitating ces-
sation of noneffective treatments. Early response detection
can also assist in the clinical translation of novel anti-
cancer agents [6]. Molecular imaging techniques such as
PET (positron emission tomography) and MRS (magnetic
resonance spectroscopy) are sensitive, noninvasive methods
for early response detection [7] and cell based studies have
shown that changes inmetabolite utilisation are earlymarkers
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of response [8]. FDG ([18F]fluoro-2-deoxy-D-glucose) is an
unsuitable tracer for imaging the prostate as it is excreted
via the kidney so patient FDG-PET scans inevitably show
high activity in the pelvic region which will obscure uptake
by the prostate gland. However prostate cancer has a high
affinity for the phospholipid metabolite, choline, and conse-
quently can be imaged using [11C]choline-PET [9]. Further,
AR activation in prostate cancer induces signalling via the
calcium/calmodulin dependent kinase kinase 2- (CAMKK2-)
AMPK signalling pathway which amongst other effects con-
trols phospholipid metabolism so inhibition of signalling
via the AR would be expected to induce early changes in
phospholipidmetabolismwhich can be probed noninvasively
using 31P-NMR spectroscopy. 31P-NMR spectroscopy detects
the concentration of several phospholipidmetabolites includ-
ing glycerophosphorylcholine (GPC) and phosphocholine
(PC) which in some cells has been shown to be associated
with proliferation rate [10].
Here prostate cancer cells untreated and treated with
flutamide, paclitaxel, or Epi-1 were subject to pulse-chase
measurements with [3H-methyl]choline (which is chemically
identical to [11C]choline) and 31P-NMR spectroscopy to
assess the modulatory effect of these drugs on phospholipid
metabolism.
2. Methods
2.1. Chemicals and Cells. Androgen receptor positive LNCaP
prostate cancer cell lines were obtained from the European
Collection of Cell Cultures (ETACC). Cells were grown
in Dulbecco’s Modified Eagle’s Medium supplemented with
glutaMAX (Gibco UK), 10% charcoal stripped serum, and
10,000 units penicillin/10,000𝜇g and streptomycin per 100ml
of medium. Cells were supplemented in all experiments
with the androgen R1881 (1 𝜇g/ml). [3H-methyl] choline
(2.96 TBq/mmol) was obtained fromAmerican Radiochemi-
cal Corporation Inc., USA. All chemicals were obtained from
Sigma-Aldrich (Poole, UK) unless otherwise stated.
2.2. Determination of Drug Induced Cell Growth Inhibition
Using the MTT Assay. The cell growth inhibiting effect of
anticancer drugs was initially tested using the MTT assay.
LNCaP cells in medium (100 𝜇l) were seeded into 96-well
plates (75,000 cells/ml) and incubated for 24 h at 37∘C in
a CO
2
incubator and then treated with a range of drug
concentrations for 72 h at 37∘C. Cell number in each well is
then determined using the 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyl tetrazolium bromide (MTT) dye which is converted
to a purple colour by mitochondria in viable cells. The
intensity of the purple colour, which is proportional to the
cell number, was then determined using a scanningmultiwell
plate reader (MR5000Dynatech Laboratories Inc., USA)with
the absorbance at 540 nm.
2.3. Pulse-Chase [3𝐻-methyl]choline. The pulse-chase tech-
nique simulates exposure of cancer cells in patients to blood
levels of [11C]choline. LNCaP cells (106 in 5ml of medium)
were seeded in 25 cm2 flasks and allowed to establish for 24 h.
The cells were then either left untreated or treated with drugs
for 48 h after which medium was removed and replaced with
1ml of medium containing 37KBq of [3H-methyl] choline.
After 15mins, the cells were rapidly washed 3x with ice-cold
phosphate buffered saline (Sigma, Poole, UK), then incubated
with nonradioactive medium for 1 h. Medium was collected
and radioactivity counted and the cells were trypsinized
by addition of 0.35ml of trypsin (0.05% trypsin/EDTA).
After the cells were detached, 0.35ml of medium was added
and the cells transferred to 1.5ml microfuge tubes which
were centrifuged at 200𝑔 for 5min. The cells were washed
by addition of 1ml of PBS and further centrifugation. The
supernatant and medium were combined and subject to
phosphate measurement (see below). The cells were sub-
ject to fractionation into lipid and aqueous fractions (see
below).
2.4. Lipid and Aqueous Fractionation. Cells were suspended
in 0.375ml of chloroform :methanol (1 : 2) and left on ice
for 1 h with occasional mixing. Separation of the phases was
then achieved by addition of 125 𝜇l of 10mMTRIS buffer and
125 𝜇l of chloroform followed by centrifugation at 10,000𝑔 for
10min at 4∘C.The upper phase was then removed and subject
to phosphate measurement. The lipid phase was removed by
carefully accessing with a pipette tip through the cell residue
at interface. Radioactivity in the lipid phase was measured
by scintillation counting. The cell residue (mainly protein)
was dried in the microfuge tubes and then dissolved in 100 𝜇l
of NaOH (1M). A protein assay (Bicinchoninic Acid Protein
Assay Kit, Sigma, UK) was carried out on the dissolved pellet
after neutralisation with HCl and used to normalise the data
for differences in cell number between treated and untreated
cells.
2.5. Determination of Proportion of Phosphorylated [3𝐻-meth-
yl]choline. Aqueous extracts and cell washes were subject
to measurement of phosphorylated [3H-methyl]choline [11,
12]. Briefly, the total radioactivity in each of the sample
was measured using part of each sample and correcting
for volume. Phosphates (which included any phosphorylated
[3H-methyl]choline) were precipitated by addition of equal
volumes of Ba(OH)
2
(0.3M) and ZnSO
4
(5% w/v) and cen-
trifugation at 10,000𝑔 for 10min to remove the precipitated
phosphates.Thenonphosphorylated [3H-methyl]cholinewas
then determined in the supernatant.The proportion of phos-
phorylated [3H-methyl]choline was determined by subtrac-
tion after correcting for dilution [13] from total.The total and
phosphorylated activity (including the lipid fraction) were
summated and the proportion of phosphorylated activity was
determined.
2.6. Sample Preparation for 31𝑃-NMRSpectroscopy. Cells were
seeded in 80 cm2 tissue culture flasks and allowed to establish
for 24 h. The cells were then either left untreated or treated
with drugs for 48 h after which medium was removed and
the cells washed 3x with 10ml PBS. The cells were then
detached with trypsin (3ml) and, after addition of medium
(3ml), the cells were centrifuged at 200𝑔 for 5min.The pellet
was suspended in isotonic saline and transferred to a 1.5ml
microfuge tube and washed 3x with ice-cold isotonic saline,
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Figure 1: Growth of LNCaP cells treated with paclitaxel (taxol) (a), flutamide (b), or Epi-1 (c) relative to untreated cells.
each time centrifuging at 200𝑔 for 5min at 4∘C.Thepellet was
then subject to lipid and aqueous fractionation as described
above except 10mM EDTA and a standard consisting of 1-
aminopropylphosphoric acid (0.3 𝜇moles) was added to the
initial 0.375ml of chloroform and methanol. After extraction
and phase separation, the aqueous phase was collected and
made up to a volume of 0.6ml by addition of D
2
O. The
lipid fraction was spiked with the standard tetramethylsilane
(TSP) (0.6 𝜇moles) and subject to 1H NMR analysis.
2.7. 31𝑃-NMR and 1𝐻-NMR Spectroscopy. NMR analysis
was carried out on a Bruker AVANCE III 400MHz NMR
spectrometer operating at 161.98MHz for 31P with broad-
band 1H decoupling and run overnight (to acquire 20,000
scans) at 25∘C. The parameters for each acquisition were as
follows: acquisition time 1.258 s; relaxation delay 1 s (peak
sizes were similar when 1 s or 2 s were used suggesting
complete relaxation in 1 s); pulse angle 45∘. At least three
independent experiments were carried out and analysed per
treatment. Metabolite concentrations were determined by
comparison with the standard (0.3𝜇moles) resonating at
11.8 ppm.
1H-NMR spectra, acquired on the lipid extracts, were run
for 200 scans with a relaxation delay of 5 s and a 90∘ pulse
angle.
2.8. Statistical Analysis. Significant differences between
means were tested using Student’s 𝑡-test. All experiments
were carried out at least 3 times.
3. Results and Discussion
Figure 1 shows the effect of paclitaxel, Epi-1, and flutamide on
the growth of LNCap cells. Growth inhibition of LNCaP cells
with paclitaxel achieves a plateau at about 10 nM. A similar
effect has been noted previously [14] with this drug. Both
Epi-1 and flutamide inhibited growth in a concentration-
dependent manner. For subsequent experiments, doses were
chosen that decreased growth by about 30% 5 nM paclitaxel,
40 𝜇M Epi-1, and 20 𝜇M flutamide.
Total [3H-methyl]choline uptake, percent phosphory-
lated, and percent phosphorylated in lipid are shown in Fig-
ure 2. Total uptake is unaffected by each drug treatment, but
the percentage of phosphorylated [3H-methyl]choline is sig-
nificantly (𝑝 < 0.01) decreased in cells treatedwith flutamide.
To better understand the intracellular fate of the phospho-
rylated [3H-methyl]choline, activity in the lipid fraction was
determined and found to be significantly (𝑝 < 0.01) increased
in cells treated with Epi-1. However, steady-state PtdCho
content, determined by analysis of the choline peak (Figure 3)
resonating at 3.4 ppm in the 1H spectra acquired from the
lipid phase of cell extracts, was not significantly increased in
cells treatedwith Epi (1.12±0.23 𝜇mol/mg protein) compared
with control cells (0.99 ± 0.03 𝜇mol/mg protein). PtdCho
transfer protein (PC-TP) is involved in preserving steady-
state membrane phospholipid content in cells in response to
cellular lipid efflux. PC-TP is associatedwith the steroidal 31P-
NMR spectroscopy that can detect phospholipid metabolites
in cells and cell extracts [15, 16] and is clinically translatable
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Figure 2: Total [3H-methyl]choline uptake (a), phosphorylated [3H-methyl]choline (as a % of total uptake) (b), and incorporation of
[3H-methyl]choline into lipid relative to phosphorylated [3H-methyl]choline (c) (∗ indicates statistically significant change compared with
control).
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Figure 3: 1H-NMR spectrum acquired from the lipid extract
prepared from control LNCaP cells showing location of PtdCho
resonance and the standard TMS (𝑥-axis: ppm).
[17]. Figure 4(a) shows a 31P-NMR spectrum acquired on an
aqueous extract from untreated LNCaP cells. The standard
resonates at 11.8 ppm, the phospholipidmetabolites PE (phos-
phoethanolamine) and PC (phosphocholine) resonate at 3.75
and 3 ppm, respectively, inorganic phosphorus resonates at
1.2 ppm, the phospholipid catabolites GPE and GPC resonate
at 0.5 and −0.5 ppm, respectively, PCr resonates at −3.1,
and 𝛾, 𝛼, and 𝛽 NTP (nucleotide triphosphates) resonate
at −7.5 ppm, −11, and −22 ppm, respectively. Phosphorus in
NAD (nucleotide adenine dinucleotide) resonates at −11.5
and DPDE (diphosphodiesters) at −13 ppm.
Figure 5 shows mean (±SD) of each metabolite. In com-
mon with other studies [15], phospholipid metabolism was
examined after 48 h treatments [18]. There is no significant
change in the content of any of the metabolites in cells
treated with either flutamide or paclitaxel compared with
untreated cells. However treatment of prostate cancer cells
with Epi-1 was associated with decreased levels of GPC and
GPE to undetectable levels. A study [19] has shown that
the level of GPC in aggressive basal-type breast tumours is
greater than in the less aggressive luminal tumours. A study
[20] using a inhibition of HIF1 inhibitor PX-478 which, in
common with the AR-stimulated prostate cancer growth [21,
22], is associated with AMPK signalling [23] demonstrated
decreased GPC in human colorectal cancer cells. A recent
study [24] has demonstrated excellent resolution of PC,
PE, GPC, and GPE 31P-NMR spectra in vivo from patients
with prostate cancer using a 7 T system suggesting that this
method could be utilised in detecting response to Epi-1.
GPC and GPE are phospholipid degradation products
and have been considered measures of dynamic membrane
turnover [19]. The complex role of GPC in cancer is very
difficult to understand and elucidating the mechanism of
therapy-induced changes in GPC is likely to be challenging
[25]. GPC/E levels are the net result of several different
enzyme activities including Phospholipase A2, group IVA/B,
Lysophospholipase 1/2, Phospholipase B1, Phospholipase
A2G3, Phospholipase A2G10, and Phospholipase A2G12A
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Figure 4: 31P-NMR spectra acquired from chemical extracts (aqueous) prepared from untreated LNCaP cells (a) or LNCaP cells
treated for 48 h with paclitaxel (5 nM) (b), Epi-1 (40𝜇M) (c), or flutamide (20 𝜇M) (d). (1APPA: standard; PE: phosphoethanolamine;
PC: phosphocholine; Pi: inorganic phosphate; GPE: glycerophosphorylethanolamine; GPC: glycerophosphorylcholine; NTP: nucleoside
triphosphates; NAD: nucleotide adenine dinucleotide; DPDE: diphosphodiester sugars).
and their regulation is difficult to interpret [19]. Cellular
content of GPE and GPC has recently been shown to at
least in part reflect [26] the activity of the enzyme GPC-
phosphodiesterase. Futurework to determine themechanism
of decreased GPC and GPE could concentrate on evaluation
of the expression of these enzymes in Epi-1-treated cells.
4. Conclusions
The protein-protein interaction inhibitor Epi-1 induces
changes in phospholipid metabolism which could be
exploited in monitoring response of prostate cancer to this
drug using 31P-NMR spectroscopy.
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Figure 5: Mean (±SD) 31P-NMR spectroscopy detectable metabo-
lite content (𝜇mol/mg protein) in control (untreated (black)), and
pactitaxel (5 nM) (white), Epi-1 (40 𝜇M) (squares), or flutamide
(20 𝜇M) (diagonal) treated LNCaP cells.
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